Abiraterone Accord Uni Eropa - Swedia - EMA (European Medicines Agency)

abiraterone accord

accord healthcare s.l.u. - abirateronacetat - prostatiska neoplasmer - endokrin terapi - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Abiraterone Mylan Uni Eropa - Swedia - EMA (European Medicines Agency)

abiraterone mylan

mylan ireland limited - abirateronacetat - prostatiska neoplasmer - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Abiraterone Krka Uni Eropa - Swedia - EMA (European Medicines Agency)

abiraterone krka

krka, d.d., novo mesto - abirateronacetat - prostatiska neoplasmer - endokrin terapi - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Amvuttra Uni Eropa - Swedia - EMA (European Medicines Agency)

amvuttra

alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - andra nervsystemet droger - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Esmocard 10 mg/ml Injektionsvätska, lösning Swedia - Swedia - Läkemedelsverket (Medical Products Agency)

esmocard 10 mg/ml injektionsvätska, lösning

orpha-devel handels und vertriebs gmbh - esmololhydroklorid - injektionsvätska, lösning - 10 mg/ml - esmololhydroklorid 10 mg aktiv substans - esmolol

Duphalac Frukt 667 mg/ml Oral lösning Swedia - Swedia - Läkemedelsverket (Medical Products Agency)

duphalac frukt 667 mg/ml oral lösning

bgp products ab - laktulos - oral lösning - 667 mg/ml - laktos (vattenfri) hjälpämne; laktulos 667 mg aktiv substans - laktulos

Oxytocin Grindeks 16,7 mikrogram/ml Injektions-/infusionsvätska, lösning Swedia - Swedia - Läkemedelsverket (Medical Products Agency)

oxytocin grindeks 16,7 mikrogram/ml injektions-/infusionsvätska, lösning

as grindeks - oxytocin - injektions-/infusionsvätska, lösning - 16,7 mikrogram/ml - oxytocin 16,7 mikrog aktiv substans - oxytocin

Oxytocin Grindeks 8,3 mikrogram/ml Injektions-/infusionsvätska, lösning Swedia - Swedia - Läkemedelsverket (Medical Products Agency)

oxytocin grindeks 8,3 mikrogram/ml injektions-/infusionsvätska, lösning

as grindeks - oxytocin - injektions-/infusionsvätska, lösning - 8,3 mikrogram/ml - oxytocin 8,3 mikrog aktiv substans - oxytocin

Septocaine forte 40 mg/ml + 10 mikrogram/ml Injektionsvätska, lösning Swedia - Swedia - Läkemedelsverket (Medical Products Agency)

septocaine forte 40 mg/ml + 10 mikrogram/ml injektionsvätska, lösning

septodont - adrenalintartrat; artikainhydroklorid - injektionsvätska, lösning - 40 mg/ml + 10 mikrogram/ml - adrenalintartrat 18,2 mikrog aktiv substans; artikainhydroklorid 40 mg aktiv substans; natriummetabisulfit hjälpämne - kombinationer

Septocaine 40 mg/ml + 5 mikrogram/ml Injektionsvätska, lösning Swedia - Swedia - Läkemedelsverket (Medical Products Agency)

septocaine 40 mg/ml + 5 mikrogram/ml injektionsvätska, lösning

septodont - adrenalintartrat; artikainhydroklorid - injektionsvätska, lösning - 40 mg/ml + 5 mikrogram/ml - natriummetabisulfit hjälpämne; adrenalintartrat 9,1 mikrog aktiv substans; artikainhydroklorid 40 mg aktiv substans - kombinationer